IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology

Journal of Proteome Research

Volumn 7, Issue 9, 2008, Pages 3668-3677

  Hao, Yuan ^a   Yu, Yingyan ^a   Wang, Lishun ^b   Yan, Min ^a   Ji, Lun ^a   Qu, Ying ^a   Zhang, Jun ^a   Liu, Bingya ^a   Zhu, Zhenggang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antibody microarray; Biomarker; Clinical proteomics; Diagnosis; Gastric carcinoma; H2B histone; IPO 38; Predicting prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN IPO 38; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; N L116 ANTIGEN, HUMAN; N-L116 ANTIGEN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; STOMACH CANCER; UPREGULATION; BLOOD; CASE CONTROL STUDY; FLUORESCENT ANTIBODY TECHNIQUE; MASS SPECTROMETRY; MIDDLE AGED; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, NUCLEAR; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; MIDDLE AGED; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 55249089246     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr700638k     Document Type: Article

References (41)

1. Landis, S. H.; Murray, T.; Bolden, S.; Wingo, P. A. Cancer statistics 1998. CA Cancer J. Clin. 1998, 48, 6-29.
2. Parkin, D. M.; Pisani, P.; Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 1999, 80, 827- 841.
3. Yamazaki, H.; Oshima, A.; Murakami, R.; Endoh, S.; Ubukata, T. A long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer 1989, 63. 613-617.
4. Kodera, Y.; Ito, S.; Yamamura, Y.; Mochizuki, Y.; Fujiwara, M.; Hibi, K.; Ito, K.; Aktyama, S.; Nakao, A. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann. Surg. Oncol. 2003, 10, 898-902.
5. Kodama, I.; Koufuji, K.; Kawabata, S.; Tetsu, S.; Tsuji, Y.; Takeda, J.; Kakegawa, T. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int. Surg. 1995, 80 (1), 45-48.
6. Ohuchi, N.; Takahashi, K.; Matoba, N.; Sato, T.; Taira, Y.; Sakai, N.; Masuda, M.; Mori, S. Comparison of serum assays for TAG- 72, CA19-9 and CEA in gastrointestinal carcinoma patients. Jpn. J. Clin. Oncol. 1989, 19 (3), 242-248.
7. Ychou, M.; Duffour, J.; Kramar, A.; Gourgou, S.; Grenier, J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis. Markers 2000, 16 (3-4), 105-110.
8. Lai, I. R.; Lee, W. J.; Huang, M. T.; Lin, H. H. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002, 49 (46), 1157-1160.
9. Carpelan-Holmstrom, M.; Louhimo, J.; Stenman, U. H.; Alfthan, H.; Haglund, C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002, 22, 2311-2316.
10. Somiari, R. I.; Somiari, S.; Russell, S.; Shriver, C. D. Proteomics of breast carcinoma. J Chromatogr., B2005, 815 (1-2), 215-225.
11. Haab, B. B.; Dunham, M. J.; Brown, P. O. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001, 2 (2), RESEARCH0004.1-0004.13.
12. Miller, J. C.; Zhou, H.; Kwekel, J.; Cavallo, R.; Burke, J.; Butler, E. B.; Teh, B. S.; Haab, B. B. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003, 3 (1), 56-63.
13. Kawada, N. Cancer serum proteomics in gastroenterology. Gastroenterology 2006, 730(6), 1917-1919.
14. Ren, H.; Du, N.; Liu, G.; Hu, H. T.; Tian, W.; Deng, Z. P.; Shi, J. S. Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J. Gastroenterol. 2006, 12 (17), 2789-2792.
15. Pinchuk, V. G.; Sidorenko, S. P.; Vetrova, E. P.; Berdova, A. G.; Shlapatskaia, L. N. Monoclonal antibodies to RPMI-1788 lymphoblastoid line cells. Eksp. Onkol. 1986, 8 (6), 41-46; [article in russian].
16. Sidorenko, S. P.; Vetrova, E. P.; Iurchenko, O. V.; Shlapatskaia, L. N.; Berdova, A. G.; Elenskaia, A. M.; Bal'shin, M. D.; Gluzman, D. F. Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases. Gematol. Transfuziol. 1990, 35 (4), 19-22; [article in russian].
17. Sidorenko, S. P.; Vetrova, E. P.; Yurchenko, O. V.; Berdova, A. G.; Shlapatskaya, L. N.; Gluzman, D.F. Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma 1992, 39 (1), 3-9.
18. Mikhalap, S. V.; Lopez, F.; Shlapatskaya, L. N. Monoclonal antibody IPO-38 recognizes a novel nuclear antigen of proliferating cells. In Leucocyte Typing VI; Kishimoto, T., Eds.; Garland Publishing, Inc.: New York, NY, 1997; pp 609-610.
19. Mikhalap, S. V.; Shlapatskaya, L. N.; Berdova, A. G.; Yurchenko, O. V.; Lopes, F.; Lukyanova, N. Y.; Sidorenko, S. P. Monoclonal antibody IPO-38 in evaluation of proliferative activity of tumor cells. Exp. Oncol. 2000, 22 (Suppl. 2), 36-38.
20. Thosaporn, W.; Iamaroon, A.; Pongsiriwet, S.; Ng, K. H. A comparative study of epithelial cell proliferation between the odontogenic keratocyst, orthokeratinized odontogenic cyst, dentigerous cyst, and ameloblastoma. Oral. Dis. 2004, 10 (1), 22-26.
21. Perkins, N. J.; Schisterman, E. F. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am. J. Epidemiol. 2006, 163 (7), 670- 675.
22. Schisterman, E. F.; Perkins, N. J.; Liu, A; Bondell, H. Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples. Epidemiology 2005, 16, 73- 81.
23. Schisterman, E. F.; Faraggi, D.; Reiser, B. Adjusting the generalized ROC curve for covariates. Stat. Med. 2004, 23 (21), 3319-3331.
24. Broil, R.; Mahlke, C; Best, R.; Schimmelpenning, H; Strik, M. W.; Schiedeck, T; Bruch, H. P.; Duchrow, M. Assessment of the proliferation index in gastric carcinomas with the monoclonal antibody MIB 1. J Cancer Res. Clin. Oncol. 1998, 124 (1), 49-54.
25. Davessar, K.; Pezzullo, I. C.; Kessimian, N.; Hale, I. H.; Jauregui, H. O. Gastric adenocarcinoma: prognostic significance of several pathologic parameters and histologic classifications. Hum. Pathol. 1990, 21 (3), 325-332.
26. Luger, K.; Mader, A. W.; Richmond, R. K.; Aergent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389, 251-260.
27. Jackson, V.; Chalkley, R. Histone segregation on replicating chromatin. Biochemistry 1985, 24 (24), 6930-6938.
28. Bonenfant, D.; Towbin, H.; Coulot, M.; Schindler, P.; Mueller, D. R.; van Oostrum, J. Analysis of dynamic changes in post-translational modifications of human histones during cell cycle by massspectrometry. Mol. Cell. Proteomics 2007, 6, 1917-1932.
29. Beck, H. C; Nielsen, E. C; Matthiesen, R.; Jensen, L. H.; Sehested, M.; Finn, P.; Grauslund, M.; Hansen, A. M.; Jensen, O. N. Quantitative proteomic analysis of post-translational modifications of human histones. Mol. Cell. Proteomics 2006, 5 (7), 1314-1325.
30. Kuo, M. H.; Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. BioEssays 1998, 20 (8), 615-626.
31. Cheung, P.; Allis, C. D.; Sassone-Corsi, P. Signaling to chromatin through histone modifications. Cell 2000, 103 (2), 263-271.
32. Kouzarides, T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 2002, 12 (2), 198-209.
33. Robzyk, K.; Recht, J.; Osley, M. A. Rad6-dependent ubiquitination of histone H2B in yeast. Science 2000, 287 (5452), 501-504.
34. Nathan, D.; Ingvarsdottir, K.; Sterner, D. E.; Bylebyl, G. R.; Dokmanovic, M.; Dorsey, J. A.; Whelan, K. A.; Krsmanovic, M.; Lane, W. S.; Meluh, P. B.; Johnson, E. S.; Berger, S. L. Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev. 2006, 20 (8), 966-976.
35. Nathan, D.; Sterner, D. E.; Berger, S. L. Histone modifications: Now summoning sumoylation. Proc. Natl. Acad. Set U.SA. 2003, 100 (23), 13118-13120.
36. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 2000, 403, 41-45.
37. Cheung, P.; Allis, C. D.; Sassone-Corsi, P. Signaling to chromatin through histone modifications. Cell 2000, 103, 263-271.
38. Jenuwein, T.; Allis, C. D. Translating the histone code. Science 2001, 293, 1074-1080.
39. Altheim, B. A.; Schultz, M. C. Histone modification governs the cell cycle regulation of a replication-independent chromatin assembly pathway in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A 1999, 96 (4)), 1345-1350.
40. Brenner, R. M.; Slayden, O. D.; Rodgers, W. H.; Critchley, H. O.; Carroll, R.; Nie, X. j.; Mah, K. Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum. Reprod. 2003, 18, 1185-1193.
41. Davidson, E. J.; Morris, L. S.; Scott, I. S.; Rushbrook, S. M.; Bird, K.; Laskey, R. A.; Wilson, G. E.; Kitchener, H. G; Coleman, N.; Stern, P. L. Minichromosome maintenance (Mem) proteins, cyclin' Bl and Dl, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br. J. Cancer 2003, 88, 257-262.